Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07592689 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
A Phase 3 study, sponsored by Definium Therapeutics US.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
NCT07592689 is a Phase 3 study that is actively recruiting participants, run by Definium Therapeutics US. The registered enrollment target is 165 participants.
The verdict
NCT07592689, a Phase 3 study, is actively recruiting participants, sponsored by Definium Therapeutics US.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
Study Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
Interventions
- OTHER Placebo
- DRUG DT120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2026-05-10 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07592689
The ClinicalTrials.gov registry entry for NCT07592689 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Definium Therapeutics US, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07592689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07592689 about?
NCT07592689 is a clinical study titled "A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)". A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
What is the current status of trial NCT07592689?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2026-05-10. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07592689?
The interventions under investigation include: Placebo (OTHER), DT120 (DRUG).
Who is sponsoring clinical trial NCT07592689?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.